The diagnostic and therapeutic efficacy of cancer-targeted nanoparticles in clinical applications is limited by a lack of understanding of their tumour targeting properties. Typically, nanoparticles are believed to target tumours via passive (e.g., blood vessel leakiness, such as in the enhanced permeability and retention (EPR) effect 1, 2 ) and/or active (e.g., ligand-mediated [2] [3] [4] targeting. With and without ligandmediated targeting, single-walled carbon nanotubes (SWNTs) have been shown to display some of the highest tumour uptake values of all intravenously injected nanoparticles 5 . For this reason, we chose to examine SWNT targeting in detail.
Currently, most studies visualise nanoparticle localization using bulk imaging modalities such as MRI, ultrasound, and whole body fluorescence 6 Recently, we demonstrated that SWNTs can target tumour via both passive and active mechanisms in a mouse tumour model, including extravasation from the bloodstream into tumour interstitium (passive) and ligand-mediated targeting to tumour cells and to tumour blood vessels (active) 7 . However, we found that the uptake of SWNTs into tumours could not be explained by these mechanisms alone 7 .
In this work, we identify and characterise the other mechanisms mediating the uptake of SWNTs into tumour by dynamic imaging on the microscale and determine if these other mechanisms are ligand-mediated in nature. Based on initial observations 7 , we hypothesised that cells in the blood take up nanoparticles and deposit them in the tumour, with increased uptake due to ligand targeting.
Uncovering these alternative tumour uptake mechanisms could lead to new ways to increase efficient nanoparticle deposition in tumour, improved methods for tumour diagnosis or treatment and, potentially, to novel ways to influence an immune cell subset for cancer therapy and other applications.
Circulating Blood Cells Rapidly Internalize SWNTs
To monitor SWNTs in living mice, we employed intravital microscopy (IVM) 8 with a dorsal skinfold chamber mouse tumour model 7 (Supplementary Fig. S1 ).
Three days after dorsal window implantation, tumour cells were implanted under the window. Ten days later, SWNTs (plain or peptide-modified (RGD or RAD), all with cy5.5; Fig. 1b) were injected via the tail vein. We observed the influx of SWNTs We discovered that ~8µm circulating cells take up SWNTs using FACS (Fluorescence-Activated Cell Sorting) and dark-field fluorescence microscopy (see . We verified that SWNTs were taken up into the circulating blood cells (Fig. 1c) , not simply Cy5.5 dye alone, by applying hyperspectral imaging to compare the spectral signatures of a plain SWNT (modified only with PEG and Cy5.5) solution to those of FACS-sorted SWNT-positive cells ( Fig. 1c-d) ; a negative control of mice never injected with SWNTs showed no SWNT signal in the cells (Supplementary Fig. S2 ). The hyperspectral analysis also provides a map of the subcellular spatial distribution of SWNTs. SWNTs appear dispersed throughout much of the cell cytoplasm and sparsely around the cell membrane (Fig. 1c) . This suggests that SWNTs are predominantly taken up into the cells, rather than binding to the cell surface.
Selective Uptake of SWNTs by Inflammatory Blood Monocytes
Intrigued by the SWNT uptake into cells, we sought to define the cell subsets.
In some mice, submandibular bleeding was performed 2h and 6h post-injection (p.i.) We employed high-dimensional 13-parameter (11-colors) FACS analysis to identify the subset(s) of immune cells that takes up SWNTs in the blood. SWNTs reputedly can, and generally do, enter a wide variety of cells via energy-dependent and independent uptake mechanisms 9, 10 . Based on previous extensive studies, it was expected that phagocytes such as circulating macrophages and their precursors [11] [12] [13] , among other circulating cells, would take up SWNTs.
In contrast, we show that of all myeloid cells, only a single monocyte subset, Ly-6C hi monocytes, displayed substantial SWNT uptake; circulating Ly-6C hi monocytes took up SWNTs with exquisite selectivity (nearly 100% of Ly-6C hi , CD11b + monocytes) within 2h p.i. (Fig. 2) . Other circulating white blood cells, including phagocytic cells, took up negligible amounts of SWNTs (e.g., ~3% of neutrophils, <1% of Ly-6C low monocytes, <1% of lymphocytes, etc.; Fig. 2 ). High selectivity for the Ly-6C hi subset was still observed at 6h p.i. in blood (Fig. 2) , after freely-circulating SWNTs had already cleared from vasculature 8 . We do not yet understand the mechanisms (e.g., specific surface receptors) by which Ly-6C hi monocytes selectively recognize and internalize SWNTs. Nevertheless, intriguingly the uptake of SWNTs by Ly-6C hi monocytes does not activate these cells 6h after injection ( Supplementary Fig. S3 ).
SWNT Surface Functionalization Enhances Monocyte Uptake into Tumour
We observed that SWNT-laden monocytes entered tumour interstitium ( 14, 15 ; RAD peptide serves as a non-specific control. Intriguingly, on day 1 p.i. we observed significantly more SWNT-laden monocytes in tumour interstitium in the RGD-SWNT injected group compared to the RAD-SWNT group (p=0.01, Fig. 3b ).
Interestingly, monocytes continued to home to tumour over time in mice that received RGD-SWNTs, with more SWNT-laden monocytes in the tumour interstitium in the RGD-SWNT condition than the RAD-SWNT condition on day 7 p.i. (p<0.0005, Fig. 3b) ; the difference between RGD and RAD conditions was even greater on day 7 than on day 1 (Fig. 3b) . The integrin-specific peptide on the SWNT surface thus surprisingly appears to help drive monocytes into tumour interstitium (previously, it was known only that RGD can assist free nanoparticle accumulation in tumour 7, 14, 15 ); this is consistent with our analysis of monocyte interactions with the tumour vasculature in the RGD-SWNT group (see Supplementary Fig. S4 and Supplementary Information for discussion) and the trend of increasing total SWNT accumulation in tumour ( Supplementary Fig. S5 ), suggesting the phenomenon may be ligandmediated.
Efficient nanoparticle delivery is a major obstacle confronting cancer nanotechnology 14, 16 . In this context, we asked whether this mechanism (targeting tumour via a key monocyte subset) has a substantial effect on the total amount of SWNTs accumulating in tumour. We assessed the effect by computing the proportion of SWNTs in tumour contained within monocytes compared with the total amount of SWNTs in the tumour (which may arrive due to other targeting mechanisms such as extravasation, etc. 7 ). The proportion of SWNT uptake into tumour due to monocyte uptake and infiltration depended on the peptide conjugated to SWNTs: nearly ¼ of RGD-SWNTs in the tumour on day 1 p.i. were due to this mechanism ( Fig. 3c) , which was significantly more than that in the plain or RAD-conjugated SWNT injected mice (p<0.0001 and p<0.05, respectively) in which ~10-15% of SWNT uptake was due to monocyte delivery. Other, more conventional uptake mechanisms account for the remainder of SWNT uptake into tumour 7 .
Possible sources of error, such as autofluorescence, are incorporated in the nonmonocyte-driven uptake mechanisms, making our estimates of SWNT uptake due to monocytes a conservative lower bound.
Conclusions
While the EPR effect enables SWNTs to reach the tumour 7 , here we demonstrate that SWNTs can also enter the tumour by uptake of cells circulating in the blood. This delivery mechanism can account for a considerable proportion (almost 25%) of SWNTs delivered to the tumour. The largest advantage afforded by this mechanism in oncology is that it is independent of the EPR effect and therefore of the enormous heterogeneity in extravasation that exists across different tumour types, particularly in humans; a common recent theme in the literature is the heterogeneity of the EPR effect in human cancers, including uncertainty in the degree of its effect in clinical cases 8, 17 . A Trojan Horse mechanism in which the nanoparticles are selectively delivered to tumour via circulating blood cells is likely much more reliable for all solid tumours and may thus be more translatable to human disease for both diagnostic and therapeutic efficacy. A second advantage arises from the fact that hypoxic and necrotic tumour regions, rendered inaccessible to nanoparticles delivered via typical targeting mechanisms via the vascular system 18, 19 , can now be reached with this mechanism; Ly-6C hi monocytes and the tumour-associated macrophages (TAMs) into which they differentiate are attracted to therapeutically critical hypoxic/necrotic tumour regions 20 , which could enable access of SWNTs to resistant tumour cells. A third advantage of this mechanism is that the nanoparticles are not limited by circulation time for uptake into tumour, but only by the circulation time of the immune cells taking them up in the blood, enabling the nanoparticles to be delivered continuously to tumour over a period of days. Additionally, it is important to note that while nanoparticles delivered to tumour generally have been assumed to be free to bind directly to tumour cells, here we find that a considerable proportion are sequestered in monocytes/macrophages and thus presumably unable to attach to the tumour cell surface unless they are eventually released. We further note here that in contrast to conventional targeting assumptions, nanoparticles taken up into tumour via this targeting mechanism are independent of the EPR effect and thus independent of critical EPR concerns about how nanoparticle properties (e.g., nanoparticle size, shape, and surface charge) may affect EPR. These properties may affect nanoparticles' ability to enter monocytes, so future work will be required to determine if other types of nanoparticles, such as quantum dots and iron oxide nanoparticles amongst others 14, 21 , can be delivered into tumour beds similar to the mechanism we report here.
While the Trojan Horse mechanism described above may be highly advantageous for delivery, it relies on innate homing of monocytes alone. Our data suggest that RGD on the SWNT surface amplifies monocyte deposition in tumour (Fig. 3b) , increasing the amount of SWNTs delivered (Fig. 3c ) both in absolute numbers and as a proportion of total SWNT accumulation. This increased infiltration may be due to interactions between RGD and the vascular endothelial surface ( Supplementary Fig. S4 , discussed in Supplementary Information).
Depending on peptide, between ~10-25% of total SWNTs found in the tumour were conservatively estimated to be due to monocyte uptake, making it a major targeting component. Indeed, this mechanism of uptake and tumour homing is likely partially responsible for SWNTs being one of the best known tumour targeting agents, with uptake of 10-15% ID/g 5 . Perhaps this is because monocytes allow continued accumulation of SWNTs: monocytes loaded with SWNTs continue to accumulate in tumour interstitium up to 7-9 days p.i. based on intravital microscopy ( Fig. 3b) and the trends observed in Raman imaging of intrinsic SWNT signal (Supplementary Fig.   S5 ). The ability to increase the uptake of monocytes in tumours ultimately might be exploited to improve immune-mediated cancer therapy using a variety of therapeutic strategies 18, 22 , potentially including induction of monocytes to become tumouricidal. In future applications, monocytes could be re-programmed by nanoparticles [23] [24] [25] [26] to help destroy or image tumours 24 . For example, because CD40-activated macrophages are tumouricidal 27 and Ly-6C hi monocytes differentiate into macrophages within tumours 28 , SWNTs might be equipped with activating molecules to provide a superior 29 nanoparticle-based activation trigger and RGD could be used to increase the number of macrophages to enhance tumour destruction.
Direct, selective delivery of nanoparticles and drugs into circulating immune cells has been a long-sought goal in medicine for wide-ranging applications 12, 18, 30 .
Yet highly selective uptake has proven extremely challenging even in optimized in vitro/ex vivo conditions [30] [31] [32] [33] , with most strategies displaying somewhat promiscuous uptake across several immune cell types. Ly-6C hi monocytes represent a premier cell group for increasing nanoparticle delivery to disease sites in general and toward novel routes for imaging and therapeutic interventions. This is because their native phenotype enables them to selectively infiltrate affected tissues in many diseases, such as to cancer via a Trojan Horse mechanism. Ly-6C hi monocytes are phenotypically, functionally, and physically (e.g., size, morphology) distinct from other monocyte subsets, including the other monocyte subset present in blood, Ly-6C low monocytes 34, 35 . Furthermore, Ly-6C hi monocytes account for only 2-5% of all circulating white blood cells 35, 36 . Targeting this monocyte subset may be particularly important in cancer applications because Ly-6C hi monocytes differentiate into TAMs 28 , which form a critical component of the tumour stroma. In particular, TAMs have been implicated in the pathogenesis of cancer, requiring new strategies that selective SWNT targeting could potentially help provide. Because it is difficult for injected particles to reach often inaccessible TAMs deep in tumour hypoxic regions 18, 37 , targeting Ly-6C hi monocytes in blood could avoid this critical limitation: our SWNTs enter the monocytes in blood, monocytes then undergo diapedesis into tumour, become TAMs, and the TAMs could carry them to hypoxic regions. Moreover, our approach involves direct intravenous injection, thereby avoiding the need for ex vivo labeling of the cells 18 (though notably the ex vivo labeling method remains an option to further increase the amount of SWNTs delivered to the tumour). Last, with respect to eventual human clinical translation, we note that murine Ly-6C hi monocytes display high genetic homology and functionality to an analogous subset of monocytes in humans 34 , the CD14 hi CD16 -subset 38 .
We do not yet understand the mechanism for the selectivity of our SWNTs to Ly-6C hi monocytes. We also do not fully understand the mechanism of increased monocyte targeting to tumour via RGD, although imaging data indicates it is likely due to interaction between RGD and tumour vascular endothelium. Other limitations of our study include concerns about SWNT toxicity; however, we note that the excellent selectivity suggests that likely the main cell type of concern is Ly-6C hi monocytes (though it is possible inflammation or other effects could arise indirectly via the monocytes through released cytokines, antigen presentation, etc.).
Unlike other studies that have shown deleterious effects of nanotubes (e.g., multiwalled, non-functionalized nanotubes 39 ) on monocytes, our single-walled, biocompatible nanotubes do not activate monocytes 6h p.i. (Supplementary Fig. S3 ), indicating that SWNTs do not exert major effects on the monocytes based on surface marker analysis. Not only do SWNTs appear to be non-toxic to monocytes and mice in general 40 , but they can be protective/therapeutic to tissues as sensitive as the brain 41 . Nevertheless, we are working to understand the mechanism and effects of SWNTs on monocytes in greater detail.
In closing, we have identified a novel, key mechanism for nanoparticle uptake into tumours that accounts for a considerable proportion of the total uptake into tumours. Importantly, we have demonstrated that SWNTs target a key monocyte subset in the blood with exquisite selectivity and that RGD ligands attached to SWNTs can help increase the delivery of these cells into tumour sites, effectively "programming" them to enter tumour interstitium. This work may have important implications for cancer applications of nanoparticles such as the detection and treatment of cancer in the clinic; it highlights the value of circulating monocytes for targeted delivery by exploiting the fact that monocytes can easily enter and travel throughout tumours, has further implications for accurate pre-clinical identification of Ly-6C hi monocytes for disease and biological studies, and may ultimately have potential for diverse diseases such as atherosclerosis and arthritis in which this monocyte subset is directly implicated.
Methods

Nanoparticles
Peptide-and dye-conjugated SWNT bioconjugates were prepared as previously reported 8, 42 with slight modifications as follows. Raw Hipco SWNTs (Lot#R0513, Unidym, Sunnyvale, CA; diameter 0.8-1.2 nm) were placed in an aqueous solution of DSPE-PEG 5000 -Amine (NOF Corp) and sonicated for 1h, then centrifuged at 24,000 g for 6h to obtain short, PEGylated SWNTs in supernatant (100-300 nm in length 40 ). SWNTs were filtrated using 100 kDa filters (Millipore) to remove excess coating polymer. For conjugation of both RGD (arginine-glycineaspartic acid) (or control RAD (arginine-alanine-aspartic acid)) and Cy5.5 to SWNTs, conjugated on the SWNTs. Last, excess peptides were removed by filtrations using 100 kDa filters and then washed away by distilled water.
SWNT concentrations were determined spectrophotometrically (using a DU 640 from Beckman Coulter, Fullerton, CA) with an extinction coefficient of 3.1 × 10 6 mol -1 ·cm -1 at 808 nm as described previously. They were further analyzed for Cy5.5 content ( 20 Cy5.5 dyes per SWNT). The surface charge of SWNTs was analyzed using a ZetaSizer Nano ZS (Malvern Instruments, Worcestershire, U.K.) 8 .
PEG and Cy5.5 were verified to be on the SWNT surface ( Supplementary Figs. S6-7) .
Intravital Microscopy
Male retired breeder SCID mice (n=30) both bearing dorsal windows (see Supplementary Methods for details on window implantation and the tumour model) and without dorsal windows were used for this study (mice without dorsal windows were employed for harvesting blood). To perform intravital microscropy, mice were anesthetized with isoflurane and placed onto a heated plate below the objective of an IV-100 intravital microscope (Olympus, Center Valley, PA). The mice were stabilized using a stainless steel customized stage by locking the titanium dorsal chamber into place (Supplementary Fig. S1 ). Angiosense 750 (a long-circulating dye;
Perkin-Elmer, Waltham, MA) was injected to visualize the vasculature. 180 μl of 0.068 mg/ml SWNTs (RGD-SWNTs, RAD-SWNTs, or plain SWNTs) were injected into each mouse 8-10 days after tumour inoculation. Mice were imaged during injection and for the following 4 hours. They were re-imaged at 6-8, 12, and 24 hours, then every day for a week following injection, and again on day 9 postinjection. Mice were imaged using the 488, 633, and 748 nm lasers and three appropriate output channels (green, red, and near-infrared filter sets). Output channels were scanned sequentially to prevent filter bleed-through. The presence of cells within vasculature was analyzed by reference to cell-shaped and sized objects (within the red, or Cy5.5, channel) within Angiosense-marked blood vessels and via associated FACS analyses of the blood. The presence of monocytes containing SWNTs within the tumour (yet outside of the blood vessels) was also analyzed by reference to cell-shaped and sized objects within the Cy5.5 channel. All animal procedures were approved by the Stanford University Institutional Animal Care and Use Committee.
Fluorescence Activated Cell Sorting (FACS) and Flow Cytometry
Mouse blood was drawn sub-mandibularly or from the tail vein into heparin- 
Dark-Field and Hyperspectral Imaging
After isolating cells loaded with SWNTs using FACS, we analyzed these cells using a BX-51 Olympus microscope (Olympus, Center Valley, PA) equipped with CytoViva® (Auburn, AL) enhanced darkfield illumination optics, using a 100X oil and variable 0.6-1.35 NA objective with full spectrum aluminum halogen source illumination. We obtained spectral image files from 400nm-1,000nm at 2nm spectral resolution using the CytoViva® hyperspectral imaging module. CytoViva® hyperspectral image analysis software was utilized to quantify the spectral response of SWNTs and to map them within the monocytes. A plain Cy5.5-SWNT solution (TEM, Supplementary Fig. S8 ) was applied as the standard to map SWNT presence and location within extracted living monocytes with hyperspectral imaging.
Statistics
We quantified the peptide dependence (conjugated to SWNTs) of monocyte 
